Literature DB >> 8854850

Visualization of the thymus by substance P receptor scintigraphy in man.

P M van Hagen1, W A Breeman, J C Reubi, P T Postema, P J van den Anker-Lugtenburg, D J Kwekkeboom, J Laissue, B Waser, S W Lamberts, T J Visser, E P Krenning.   

Abstract

Substance P, an 11-amino acid neuropeptide, has an important role in modulating pain transmission through neurokinin 1 and 2 receptors. Substance P and other tachykinins may also play a role in the pathogenesis of inflammatory diseases. In this study we present the results concerning the metabolism of the substance P analogue [111In-DTPA-Arg1]-substance P in man, as well as the visualization of the thymus in patients with immune-mediated diseases. Twelve selected patients were investigated, comprising five with inflammatory bowel disease, one with ophthalmic Graves' disease, one with sclerosing cholangitis, one with Sjögren's syndrome, one with rheumatoid arthritis, one with systemic lupus erythematosus and two with myasthenia gravis. During and after intravenous administration of 150-250 MBq (2.5-5.0 microg) [111In-DTPA-Arg1]-substance P, blood pressure, heart rate and oxygen saturation were monitored. Radioactivity was measured in blood, urine and faeces during the 48 h after injection. Planar and single-photon emission tomographic images were obtained 4 and 24 h after injection. After administration of [111In-DTPA-Arg1]-substance P, a transient flush was observed in all patients. Degradation of [111In-DTPA-Arg1]-substance P started in the first minutes after administration, resulting in a half-life of 10 min for the total plasma radioactivity, and of 4 min for the intact radiopharmaceutical, as identified with high-performance liquid chromatography. Urinary excretion accounted for >95% of the radioactivity within 24 h post injection, and up to 0.05% was found in the faeces up to 60 h. In all patients uptake of radioactivity was found in the areolae mammae (in women), liver, spleen, kidneys and urinary bladder. In eight patients a high uptake of [111In-DTPA-Arg1]-substance P was observed in the thymus. We conclude that, despite its short half-life, [111In-DTPA-Arg1]-substance P, a new radiopharmaceutical, can be used to visualize the thymus. This may contribute to the investigation of the role of thymus in immune-mediated diseases. In addition, inflammatory sites in various diseases could be visualized.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8854850     DOI: 10.1007/bf01254476

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  27 in total

Review 1.  Substance P and the inflammatory and immune response.

Authors:  P W Mantyh
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

2.  Specific substance P binding sites in rat thymus and spleen: in vitro autoradiographic study.

Authors:  K Shigematsu; J M Saavedra; M Kurihara
Journal:  Regul Pept       Date:  1986-12-22

3.  Autoradiographic localisation and characterisation of substance P binding sites in rat knees.

Authors:  D A Walsh; M Salmon; J Wharton; P I Mapp; J M Polak
Journal:  Regul Pept       Date:  1993-07-02

4.  Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P.

Authors:  M M Chang; S E Leeman
Journal:  J Biol Chem       Date:  1970-09-25       Impact factor: 5.157

Review 5.  Immunopathology of the human thymus.

Authors:  G Tridente
Journal:  Semin Hematol       Date:  1985-01       Impact factor: 3.851

6.  Microvascular substance P binding to normal and inflamed rat and human synovium.

Authors:  D A Walsh; M Salmon; P I Mapp; J Wharton; N Garrett; D R Blake; J M Polak
Journal:  J Pharmacol Exp Ther       Date:  1993-11       Impact factor: 4.030

7.  Substance P receptor-mediated chemotaxis of human monocytes.

Authors:  M R Ruff; S M Wahl; C B Pert
Journal:  Peptides       Date:  1985       Impact factor: 3.750

8.  In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P.

Authors:  W A Breeman; M P VanHagen; H A Visser-Wisselaar; M E van der Pluijm; J W Koper; B Setyono-Han; W H Bakker; D J Kwekkeboom; M P Hazenberg; S W Lamberts; T J Visser; E P Krenning
Journal:  J Nucl Med       Date:  1996-01       Impact factor: 10.057

9.  A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.

Authors:  W A Breeman; L J Hofland; M van der Pluijm; P M van Koetsveld; M de Jong; B Setyono-Han; W H Bakker; D J Kwekkeboom; T J Visser; S W Lamberts
Journal:  Eur J Nucl Med       Date:  1994-04

10.  Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: inhibition by sodium valproate.

Authors:  V Coiro; L Capretti; R Volpi; C Davoli; A Marcato; U Cavazzini; G Caffarri; G Rossi; P Chiodera
Journal:  Neuroendocrinology       Date:  1992-10       Impact factor: 4.914

View more
  9 in total

1.  What can gallium-68 PET add to receptor and molecular imaging?

Authors:  Adil Al-Nahhas; Zarni Win; Teresa Szyszko; Aviral Singh; Sameer Khan; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12       Impact factor: 9.236

Review 2.  (68)Ga-labeled radiopharmaceuticals for positron emission tomography.

Authors:  Dinesh Shetty; Yun-Sang Lee; Jae Min Jeong
Journal:  Nucl Med Mol Imaging       Date:  2010-10-12

3.  Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes.

Authors:  Alessio Annovazzi; Calogero D'Alessandria; Elena Bonanno; Stephen J Mather; Bart Cornelissen; Christophe van de Wiele; Rudi A Dierckx; Maurizio Mattei; Graziana Palmieri; Francesco Scopinaro; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-27       Impact factor: 9.236

4.  A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent.

Authors:  Karl Plössl; Rajesh Chandra; Wenchao Qu; Brian P Lieberman; Mei-Ping Kung; Rong Zhou; Bin Huang; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

Review 5.  Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

Authors:  Marion de Jong; Dik Kwekkeboom; Roelf Valkema; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-05       Impact factor: 9.236

6.  Nuclear medicine imaging and therapy of neuroendocrine tumours.

Authors:  Martin Gotthardt; Ingrid Dijkgraaf; Otto C Boerman; Wim J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

7.  The 68Ge/ 68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?

Authors:  Wouter A P Breeman; Alfons M Verbruggen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-07       Impact factor: 9.236

Review 8.  188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy.

Authors:  Alessandra Boschi; Petra Martini; Licia Uccelli
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-19

Review 9.  The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy.

Authors:  Agnieszka Majkowska-Pilip; Paweł Krzysztof Halik; Ewa Gniazdowska
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.